



01-11-26

T5W

PTO/SB/26 (Modified)

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING  
REJECTION OVER A PRIOR PATENT**Docket No. (Optional)  
4001.002298

In re Application of: Philip E. Thorpe and Sophia Ran  
Application No.: Unknown; (Continuation of Application No. 09/351,862)  
Filed: January 10, 2006  
For: CANCER TREATMENT KITS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS

Petitioner, Board of Regents, The University of Texas System, is the owner of the entire interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as shortened by any terminal disclaimer, of prior Patent No. 6,818,213 (Serial No. 09/351,598). Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically, the Assignment of the instant application to Board of Regents, The University of Texas System, which was been recorded at reel 010262, frame 0083 in Application No. 09/351,862, and certifies that, to the best of her knowledge and belief, title of the instant application is in the name of Assignee, Board of Regents, The University of Texas System.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

January 10, 2006  
Date

By: 

Shelley P.M. Fussey  
Reg. No. 39,458  
Agent for Applicants

⊗ Terminal disclaimer fee under 37 C.F.R. § 1.20(d) should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002298.

⊗ PTO suggested wording for terminal disclaimer was:

☐ unchanged. ☒ changed (if changed, an explanation should be supplied).

**Paragraph in bold added for compliance with 37 C.F.R. § 3.73**

PTO/SB/26 (Modified)

01/12/2006 FFANAEIA 00000105 503493 09351862

01 FC:2814 65.00 DA